Twist Bioscience Preclinical Data Detailing Discovery Of Antibody Targeting Emerging Checkpoint Inhibitor Published In The Journal PLOS ONE

TB206-001 shown to be a high-affinity, cross-reactive humanized antibody antagonist of A2AR with in vivo tumor suppressing activity

TB206-001 available for out-licensing

Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the publication of a study detailing the discovery of TB206-001, a first-in-class antibody targeting adenosine A2A receptor (A2AR), a promising molecular target that could enhance cancer immunotherapy. The study titled, "Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor", was published in the journal PLOS ONE.